ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
29.95
+0.42 (1.42%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.10 - 30.20
52 week 15.64 - 32.00
Open 29.66
Vol / Avg. 1.12M/1.12M
Mkt cap 2.94B
P/E     -
Div/yield     -
EPS -0.80
Shares 99.77M
Beta 2.80
Inst. own 95%
Dec 10, 2014
ACADIA Pharmaceuticals Inc at Oppenheimer Healthcare Conference - 2:10PM EST - Add to calendar
Dec 2, 2014
ACADIA Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 10:30AM EST - Add to calendar
Nov 20, 2014
ACADIA Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London
Nov 10, 2014
Q3 2014 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Nov 10, 2014
Q3 2014 ACADIA Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -165240.00% -3314.24%
Operating margin -166626.70% -3344.72%
EBITD margin - -3337.82%
Return on average assets -28.35% -25.49%
Return on average equity -29.21% -28.41%
Employees 48 -
CDP Score - -

Address

SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO, CA 92121
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Uli Hacksell Ph.D. President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Stephen R. Davis Executive Vice President, Chief Financial Officer and Chief Business Officer
Age: 53
Bio & Compensation  - Reuters
Roger G. Mills M.D. Executive Vice President - Development, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Glenn F. Baity Vice President, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 55
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 56
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters